Hannes Hagstrom joins the Surfers to discuss the value of VCTE or other in-office MASLD monitoring due to the results providing prognoses comparable or superior to biopsy and feedback for patient self-management.
Fatty Liver Alliance Founder Mike Betel joins Roger Green to consider how patient incentives to participate in MASH clinical trials might need to change now that prescribers have an approved drug for treating MASH patients.
Patient advocates, led by GLI’s Jeff McIntyre, discuss advocates’ goals for a MASH drug label and the steps they took to communicate this information to FDA.
Last Thursday, March 14, Rezdiffra (resmetirom) became the first drug approved in the US for MASH. Five leading North American MASLD patient advocates join the Surfers to discuss their feelings about this approval along with the opportunities and challenges that lie ahead.
The conversation on Rezdiffra, the first MASH drug, wraps up with the panelists answering a inviation to discuss any other issues of interest that had not arisen in the conversation.
This conversation focuses on what panelists believe to be the major lessons the BioPharma industry should take from Madrigal’s success in bring Rezdiffra to launch.
As panelists ponder practical issues about when and to whom to prescribe Rezdiffra, they consider the benefits and shortcomings of existing NITs.
Key Opinion Leaders for Europe and the US join the Surfers the day after the first MASH drug, Rezdiffra, was approved, to discuss how they heard the news and what kinds of patients they envision as initial targets.
Last Thursday, FDA approved Rezdiffra, the first MASH drug! A global panel of key opinion leaders joins the Surfers to share excitement and discuss the implications of this landmark event.
In the podcast episode, panelists delve into the shifting landscape of diagnosing and treating F2/3 MASH patients using non-invasive tests (NITs). They discuss challenges with current diagnostic tools, upcoming blood-based tests, and the potential impact of new drugs like resmetirom and GLP-1s on treatment strategies, aiming to optimize changes in the industry once a drug is approved.
